The stock of Novo Nordisk ADR (NYSE: NVO) has increased by 2.02 when compared to last closing price of 126.88. Despite this, the company has experienced a 0.62% gain in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-29 that Novo Nordisk’s (NVO) revenues in the first quarter of 2024 are expected to have been driven by its diabetes and obesity care product sales, especially Ozempic, Rybelsus and Wegovy.
Is It Worth Investing in Novo Nordisk ADR (NYSE: NVO) Right Now?
Novo Nordisk ADR (NYSE: NVO) has a higher price-to-earnings ratio of 47.92x compared to its average ratio. NVO has 36-month beta value of 0.44. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for NVO is 3.34B, and currently, short sellers hold a 0.10% ratio of that float. The average trading volume of NVO on April 30, 2024 was 4.96M shares.
NVO’s Market Performance
The stock of Novo Nordisk ADR (NVO) has seen a 0.62% increase in the past week, with a 1.48% rise in the past month, and a 18.73% gain in the past quarter. The volatility ratio for the week is 1.66%, and the volatility levels for the past 30 days are at 1.84% for NVO. The simple moving average for the past 20 days is 3.25% for NVO’s stock, with a 22.99% simple moving average for the past 200 days.
Analysts’ Opinion of NVO
Many brokerage firms have already submitted their reports for NVO stocks, with BMO Capital Markets repeating the rating for NVO by listing it as a “Outperform.” The predicted price for NVO in the upcoming period, according to BMO Capital Markets is $163 based on the research report published on April 12, 2024 of the current year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see NVO reach a price target of $120. The rating they have provided for NVO stocks is “Overweight” according to the report published on January 23rd, 2024.
NVO Trading at 2.05% from the 50-Day Moving Average
After a stumble in the market that brought NVO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.39% of loss for the given period.
Volatility was left at 1.84%, however, over the last 30 days, the volatility rate increased by 1.66%, as shares surge +2.50% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +4.52% upper at present.
During the last 5 trading sessions, NVO rose by +0.76%, which changed the moving average for the period of 200-days by +61.88% in comparison to the 20-day moving average, which settled at $125.53. In addition, Novo Nordisk ADR saw 25.12% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for NVO
Current profitability levels for the company are sitting at:
- 0.44 for the present operating margin
- 0.85 for the gross margin
The net margin for Novo Nordisk ADR stands at 0.36. The total capital return value is set at 0.71. Equity return is now at value 87.44, with 29.90 for asset returns.
Based on Novo Nordisk ADR (NVO), the company’s capital structure generated 0.2 points at debt to capital in total, while cash flow to debt ratio is standing at 4.03. The debt to equity ratio resting at 0.25. The interest coverage ratio of the stock is 69.78.
Currently, EBITDA for the company is 112.94 billion with net debt to EBITDA at 0.11. When we switch over and look at the enterprise to sales, we see a ratio of 17.17. The receivables turnover for the company is 3.09for trailing twelve months and the total asset turnover is 0.74. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.82.
Conclusion
To put it simply, Novo Nordisk ADR (NVO) has had a better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
